Osteoblasts support megakaryopoiesis through production of interleukin-9

Blood

Volumn 129, Issue 24, 2017, Pages 3196-3209

  Xiao, Min ^a   Wang, Yongkui ^a   Tao, Chen ^a   Wang, Zhenyu ^a   Yang, Jun ^a   Chen, Zhenguo ^a   Zou, Zhipeng ^a   Li, Mangmang ^a   Liu, Anling ^a   Jia, Chunhong ^a   Huang, Bin ^a   Yan, Bo ^a   Lai, Pinglin ^a   Ding, Changhai ^a   Cai, Daozhang ^a   Xiao, Guozhi ^b,c   Jiang, Yu ^d   Bai, Xiaochun ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FIBRINOGEN RECEPTOR; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 11; INTERLEUKIN 9 RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; RECOMBINANT INTERLEUKIN 9; STAT3 PROTEIN; THROMBOPOIETIN; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR; IL9 PROTEIN, HUMAN; IL9R PROTEIN, HUMAN; IL9R PROTEIN, MOUSE; INTERLEUKIN 9; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CHEMOTHERAPY INDUCED THROMBOCYTOPENIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MEGADOSE; FEMALE; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MONOCYTE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOPROGENITOR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SERTOLI CELL; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; ANIMAL; CYTOLOGY; METABOLISM; PHYSIOLOGY; RAW 264.7 CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-9; MEGAKARYOCYTES; MICE; MULTIPROTEIN COMPLEXES; OSTEOBLASTS; RAW 264.7 CELLS; RECEPTORS, INTERLEUKIN-9; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THROMBOPOIESIS; TOR SERINE-THREONINE KINASES;

EID: 85021161054     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-11-749838     Document Type: Article

References (43)

1. Angiolillo DJ, Ferreiro JL, Price MJ, Kirtane AJ, Stone GW. Platelet function and genetic testing. J Am Coll Cardiol. 2013;62(17 Suppl): S21-S31.
2. Machlus KR Jr, Italiano JE Jr. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol. 2013;201(6): 785-796.
3. Panuganti S, Schlinker AC, Lindholm PF, Papoutsakis ET, Miller WM. Three-stage ex vivo expansion of high-ploidy megakaryocytic cells: toward large-scale platelet production. Tissue Eng Part A. 2013;19(7-8):998-1014.
4. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008;29(4): 403-440.
5. Lieberman L, Bercovitz RS, Sholapur NS, Heddle NM, Stanworth SJ, Arnold DM. Platelet transfusions for critically ill patients with thrombocytopenia. Blood. 2014;123(8): 1146-1151, quiz 1280.
6. Nieswandt B, Stritt S. Megakaryocyte rupture for acute platelet needs. J Cell Biol. 2015;209(3): 327-328.
7. Pang L, Weiss MJ, Poncz M. Megakaryocyte biology and related disorders. J Clin Invest. 2005; 115(12):3332-3338.
8. Shen Y, Nilsson SK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol. 2012;19(4): 250-255.
9. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960): 841-846.
10. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425(6960): 836-841.
11. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149-161.
12. Schepers K, Hsiao EC, Garg T, Scott MJ, Passegué E. Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice. Blood. 2012;120(17): 3425-3435.
13. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood. 2004;103(9): 3258-3264.
14. Rankin EB, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63-74.
15. Wu JY, Purton LE, Rodda SJ, et al. Osteoblastic regulation of B lymphopoiesis is mediated by Gsalpha-dependent signaling pathways. Proc Natl Acad Sci USA. 2008; 105(44):16976-16981.
16. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008; 29(4):403-440.
17. Lemieux JM, Horowitz MC, Kacena MA. Involvement of integrins alpha(3)beta(1) and alpha(5)beta(1) and glycoprotein IIb in megakaryocyte-induced osteoblast proliferation. J Cell Biochem. 2010;109(5):927-932.
18. Cheng YH, Hooker RA, Nguyen K, et al. Pyk2 regulates megakaryocyte-induced increases in osteoblast number and bone formation. J Bone Miner Res. 2013;28(6):1434-1445.
19. Kacena MA, Shivdasani RA, Wilson K, et al. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res. 2004;19(4): 652-660.
20. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2): 274-293.
21. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15(3): 155-162.
22. Tamamyan G, Danielyan S, Lambert MP. Chemotherapy induced thrombocytopenia in pediatric oncology. Crit Rev Oncol Hematol. 2016; 99:299-307.
23. Yang YC, Ricciardi S, Ciarletta A, Calvetti J, Kelleher K, Clark SC. Expression cloning of cDNA encoding a novel human hematopoietic growth factor: human homologue of murine T-cell growth factor P40. Blood. 1989;74(6): 1880-1884.
24. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010; 464(7290):852-857.
25. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. Science. 2001;294(5548):1933-1936.
26. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286(5446):1946-1949.
27. Huang B, Wang Y, Wang W, et al. mTORC1 prevents preosteoblast differentiation through the Notch signaling pathway. PLoS Genet. 2015; 11(8):e1005426.
28. Kunicki TJ, Williams SA, Nugent DJ, Yeager M. Mean platelet volume and integrin alleles correlate with levels of integrins a(IIb)b(3) and a(2)b(1) in acute coronary syndrome patients and normal subjects. Arterioscler Thromb Vasc Biol. 2012;32(1):147-152.
29. Habart D, Cheli Y, Nugent DJ, Ruggeri ZM, Kunicki TJ. Conditional knockout of integrin a2b1 in murine megakaryocytes leads to reduced mean platelet volume. PLoS One. 2013; 8(1):e55094.
30. Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133(16):3231-3244.
31. Kaplan MH, Hufford MM, Olson MR. The development and in vivo function of T helper 9 cells. Nat Rev Immunol. 2015;15(5): 295-307.
32. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 2010;10(10):683-687.
33. Goswami R, Kaplan MH. A brief history of IL-9. J Immunol. 2011;186(6):3283-3288.
34. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of NF-kappaB is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008;22(11): 1490-1500.
35. Stassen M, Müller C, Arnold M, et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol. 2001;166(7):4391-4398.
36. Dan HC, Baldwin AS. Differential involvement of IkappaB kinases alpha and beta in cytokine-and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol. 2008; 180(11):7582-7589.
37. Sun S, Wang W, Latchman Y, Gao D, Aronow B, Reems JA. Expression of plasma membrane receptor genes during megakaryocyte development. Physiol Genomics. 2013;45(6): 217-227.
38. Fujiki H, Kimura T, Minamiguchi H, et al. Role of human interleukin-9 as a megakaryocyte potentiator in culture. Exp Hematol. 2002;30(12): 1373-1380.
39. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapyassociated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002; 359(9324):2145-2152.
40. Emerson SG. Thrombopoietin, HSCs, and the osteoblast niche: holding on loosely, but not letting G0. Cell Stem Cell. 2007;1(6): 599-600.
41. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365(8):734-741.
42. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369(6481): 568-571.
43. Kaye JA. Clinical development of recombinant human interleukin-11 to treat chemotherapyinduced thrombocytopenia. Curr Opin Hematol. 1996;3(3):209-215.